Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

NCT00202917 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: Fludarabine
DRUG: Thiotepa
DRUG: Melphalan
DRUG: OKT-3
PROCEDURE: CD3/CD19 depletion on CliniMACS

Sponsor

University Hospital Tuebingen